Truist Financial Corp Sells 23,349 Shares of Abbott Laboratories $ABT

Key Points

• Truist Financial Corp trimmed its Abbott stake by 1.8% in Q4, selling 23,349 shares and leaving it with 1,244,882 shares valued at about $155.97 million (roughly 0.07% of ABT).
• Several analysts cut price targets in mid‑April but the consensus remains a Moderate Buy with an average target of $119.43; Abbott beat quarterly EPS estimates ($1.15 vs. $1.14), set FY2026 guidance of $5.38–$5.58, and declared a $0.63 quarterly dividend (2.8% yield).

Truist Financial Corp trimmed its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,244,882 shares of the healthcare product maker's stock after selling 23,349 shares during the period. Truist Financial Corp owned approximately 0.07% of Abbott Laboratories worth $155,971,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ABT. Invesco Ltd. increased its position in shares of Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Ninety One UK Ltd bought a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $336,815,000. Vanguard Group Inc. grew its position in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the last quarter. Alliancebernstein L.P. grew its position in Abbott Laboratories by 51.0% during the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker's stock valued at $740,140,000 after acquiring an additional 1,865,250 shares during the last quarter. Finally, Capital International Investors grew its position in Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker's stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company's stock, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the firm's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares of the company's stock, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have bought 22,200 shares of company stock valued at $2,215,100 and have sold 3,055 shares valued at $353,097. Insiders own 0.46% of the company's stock.

Analysts Set New Price Targets

ABT has been the topic of a number of recent research reports. Freedom Capital upgraded shares of Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 29th. Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Bank of America reduced their price target on shares of Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Sanford C. Bernstein reduced their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Finally, Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $119.43.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $89.51 on Monday. The firm has a market cap of $155.91 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 1.49 and a beta of 0.65. Abbott Laboratories has a fifty-two week low of $89.14 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The business has a 50 day moving average price of $104.33 and a 200-day moving average price of $115.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the prior year, the firm posted $1.09 earnings per share. The business's quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories's dividend payout ratio (DPR) is presently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.